Efficacy and safety of Black cohosh (Actaea/Cimicifuga racemosa) in the treatment of vasomotor symptoms - Review of clinical trials;Skutecznośacc i bezpieczeństwo stosowania Pluskwicy groniastej (Actaea/Cimicifuga racemosa) w leczeniu objawów naczynioruchowych - Przeglad badań klinicznych

Ginekologia Polska

Volumn 79, Issue 4, 2008, Pages 287-296

  Kanadys, Wiesław Maciej ^a,c   Leszczyńska Gorzelak, Bozena ^b   Oleszczuk, Jan ^b  

^a NZOZ Center for Medical Genetics   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c NONE   (Poland)

Author keywords

Actaea racemosa; Black cohosh; Cimicifuga racemosa; Efficacy; Safety; Vasomotor symptoms

Indexed keywords

NON PRESCRIPTION DRUG; PLANT EXTRACT;

ADULT; CIMICIFUGA; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HOT FLUSH; HUMAN; MENOPAUSE; METHODOLOGY; MIDDLE AGED; PHYTOTHERAPY; REVIEW; TREATMENT OUTCOME; WOMEN'S HEALTH;

ADULT; CIMICIFUGA; CLINICAL TRIALS AS TOPIC; DRUGS, NON-PRESCRIPTION; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 47749136179     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Rapkin A. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol. 2007, 196, 97-106.
2. Woods N, Mitchell E. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med. 2005, 118, suppl. 12B, 14-24.
3. Freeman E, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007, 10, 197-214.
4. Shanafelt T, Barton D, Adjei A, [et al]. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002, 77, 1207-1218.
5. Freedman R. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril. 1998, 70, 332-337.
6. Nelson H. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004, 291, 1610-1620.
7. Shmuely Y, Berlin J, Knauss J, [et al.]. Compliance with oral HRT in postmenopausal women in clinical trials - meta analysis. Maturitas. 2003, 46, 33-44.
8. Hill D, Weiss N, LaCroix A. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol. 2000, 182, 270-276.
9. Rossouw J, Anderson G, Prentice R, [et al.], for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288, 321-333.
10. Anderson G, Limacher M, Assaf A, [et al.], for Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004, 291, 1701-1712.
11. Hoda D, Perez D, Loprinzi C. Hot flashes in breast cancer survivors. Breast J. 2003, 9, 431-438.
12. Gupta P, Sturdee D, Palin S, [et al.]. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric. 2006, 9, 49-58.
13. Ganz P. Impact of tamoxifen adjuvant therapy on symptoms, functioning and quality of life. J Natl Cancer Inst Monogr. 2001, 30, 130-134.
14. Nelson H, Vesco K, Haney E, [et al.]. Nonhormonal therapies for menopausal hot flashes. Systematic review and meta-analysis. JAMA. 2006, 295, 2057-2071.
15. Kanadys W. Wplyw produktów i preparatów z soi na problemy zdrowotne kobiet w okresie menopauzy w świetle randomizowanych badań klinicznych (cześć 1.). Prz Menopauz. 2005, 3, 15-24.
16. Haimov-Kockman R, Hochner-Celnikier D. Hot flashes revisited: Pharmacological and herbal options for hot flashes management. What does the evidence tell us? Acta Obstet Gynecol Scand. 2005, 84, 972-979.
17. Low Dog T. Menopause: a review of botanical dietary supplement. Am J Med. 2005, 118, suppl. 12B, 98-108.
18. Geller S, Studee L. Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). 2005, 14, 634-649.
19. Shao Y, Harris A, Wang M, [et al.]. Triterpene glycosides from Cimicifuga racemosa. J Nat Prod. 2000, 63, 905-910.
20. Lai G, Wang Y, Fan L, [et al.]. Triterpenoid glycoside from Cimicifuga racemosa. J Asian Nat Prod. Res. 2005, 7, 695-699.
21. Jarry H, Harnischferger G, Duker E. Studies on endocrine effects of the contents of Cimicifuga racemosa. 2. In vitro binding of compounds to estrogen receptors. Planta Med. 1985, 51, 316-319.
22. Liu J, Burdette J, Xu H, [et al.]. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001, 49, 2472-2479.
23. Kennelly E, Baggett S, Nuntanakorn P, [et al.]. Analysis of thirteen populations of black cohosh for formononetin. Phytomedicine. 2002, 9, 461-467.
24. Jiang B, Kronenberg F Balick M, [et al.]. Analysis of formononetin from black cohosh (Actaea racemosa). Phytomedicine. 2006, 13, 477-486.
25. Seidlová-Wuttke D, Hesse O, Jarry H, [et al.]. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17 beta. Eur J Endocrinol. 2003, 149, 351-362.
26. Woo K, Park Y, Jun D, [et al.]. Phytoestrogen cimicifugoside-mediated inhibition of catecholamine secretion by blocking nicotinic acetylcholine receptor in bovine adrenal chromaffin cells. J Pharmacol Exp Ther. 2004, 309, 641-649.
27. Burdette J, Liu J, Chen S, [et al.]. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem. 2003, 51, 5661-5670.
28. Jarry H, Metten M, Spengler B, [et al.]. In vitro effects of the Cimicifuga racemosa extract BNO 1055. Maturitas. 2003, 44, suppl. 1, 531-538.
29. Rhyu M, Lu J, Webster D, [et al.]. Black cohosh (Actaea racemosa, Cimicifuga racemosa) behaves as a mixed competitive ligand and partial agonist at the human mu opiate receptor. J Agric Food Chem. 2006, 54, 9852-9857.
30. Stolze H. Der andere Weg, klimakterische Beschwerden zu behandeln. Gyne. 1982, 1, 14-16.
31. Daiber W. Klimakterische Beschwerden: ohne Hormone zum Erflog! Arztl Praxis. 1983, 35, 1946-1947.
32. Vorberg G. Therapie klimakterischer Beschwerden. Erfolgreiche hormonfreier Therapie mit Remifemin. Z Allgemeinmed. 1984, 60, 626-629.
33. Pethö A. Klimakterische Beschwerden, Umstellung einer Hormonbehandlung auf ein pflanzliches Gynäkologikum möglich? Arztl Praxis. 1987, 39, 1551-1553.
34. Schmidt M, Käufeler R, Polasek W. Wirksamkeit und Sicherheit von Traubensilberkerze (Cimicifuga racemosa, Cimifemin®) bei Menopausebeschwerden: Therapiebeobachtung unter Praxisbedingungen. J Menopause. 2005, 12, 27-32.
35. Vermes G, Banhidy F, Acs N. Yhe effects of remifemin on subjective symptoms of menopause. Adv Ther. 2005, 22, 148-154.
36. Raus K, Brucker C, Gorkow C, [et al.]. First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055. Menopause. 2006, 13, 678-691.
37. Radowicki S, Skórzewska K, Rudnicka E, [i wsp.]. W. Skuteczność i bezpieczeństwo stosowania suchego wyciagu z kłacza Cimicifuga racemosa w leczeniu objawów zespołu menopauzalnego. Ginekol Pol. 2006, 77, 678-683.
38. Sloan J, Loprinzi C, Novotny P, [et al.]. Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001, 19, 4280-4290.
39. Miller H, Li R. Measuring hot flashes: summary of a National Institutes of Health workshop. Mayo Clin Proc. 2004, 79, 777-781.
40. Warnecke G. Beeinflussung klimakterischer Beschwerden durch ein Phytotherapeutikum. Erfolgreiche Therapie mit Cimicifuga-Monoextrakt. Med Welt. 1985, 36, 871-874.
41. Lechamann W, Riedel H. Klinische und endokrinologische Untersuchungen Therapie ovarieller Ausfallserscheinungen nach Hysterektomie unter Belassug der Adnexe. Zentralbl Gynäkol. 1988, 110, 611-618.
42. Nappi R, Malavasi B, Brundu B, [et al.]. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol. 2005, 20, 30-35.
43. Liske E, Hänggi W, Henneicke-von Zepelin H, [et al.]. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med. 2002, 11, 163-174.
44. Briese V, Stammwitz U, Friede M, [et al.]. Black cohosh with or without St. John's wort for symptom-specific climacteric treatment - results of a large-scale, controlled, observational study. Maturitas 2007, 57, 405-414.
45. Osmers R, Friede M, Liske E, [et al.]. Efficacy and safety isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005, 105, 1074-1083.
46. Stoll W. Phytotherapeutikum beeinflußt atrophisches Vaginalepithel: Doppelblindversuch Cimicifuga vs Östrogenpräparat. Therapeutikon. 1987, 1, 23-31.
47. Wuttke W, Seidlová-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas. 2003, 44 suppl. 1, S67-S77.
48. Wuttke W, Raus K, Gorkow C. Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. Maturitas. 2006, 55, suppl. 1, S583-S591.
49. Frei-Kleiner S, Schaffner W, Rahlfs V, [et al.]. Cimicifuga racemosa ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas. 2005, 51, 397-404.
50. Newton K, Reed S, LaCroix A, [et al.]. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or: a randomized trial placebo. Ann Intern Med. 2006, 145, 869-879.
51. Oktem M, Eroglu D, Karahan H, [et al.]. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: A prospective, randomized trial. Adv Ther. 2007, 24, 448-461.
52. Bai W, Henneicke-von Zepelin H, Wang S, [et al.]. Efficacy an tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: A randomized, double blind, parallel-controlled study versus tibolone. Maturitas. 2007, 58, 31-41.
53. Pockaj B, Loprinzi C, Sloan J, [et al.]. Pilot evaluation of black cohosh for the treatment of hot flushes in women. Cancer Invest. 2004, 22, 515-521.
54. Pockaj B, Gallagher J, Loprinzi C, [et al.]. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol. 2006, 24, 2836-2841.
55. Jacobson J, Troxel A, Evans J, [et al.]. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. 2001, 19, 2739-2745.
56. Hernández Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas. 2003, 44 suppl. 1, S59-S65.
57. Uebelhack R, Blohner J, Graubaum H, [et al.]. Black cohosh and St. John's wort for climacteric complaints. A randomized trial. Obstet Gynecol. 2006, 107, 247-255.
58. Chung D, Kim H, Park K, [et al.]. Black cohosh and St. John's wort (GYNO-Plus®) for climacteric symptoms. Yonsei Med J. 2007, 48, 289-294.
59. Sammartino A, Tommaselli G, Gargano V, [et al.]. Short-term effects of a combination of isoflavones, lignans and Cimicifuga racemosa on climacteric-related symptoms in postmenopausal women: A double-blind. randomized, placebo-controlled trial. Gynecol Endocrinol. 2006, 22, 646-650.
60. Verhoeven M, van der Mooren M, van de Weijer P, [et al.]. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause. 2005, 12, 412-420.
61. Cancellieri F, De Leo V, Genazzani A, [et al.]. Efficacy on menopausal neurovegetative symptoms and some plasma lipids blood levels of an herbal product containing isoflavones and other plant extracts. Maturitas. 2007, 56, 249-256.
62. Rotem C, Kaplan B. Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study. Gynecol Endocrinol. 2007, 23, 117-122.
63. Low Dog T, Powell K, Weisman S. Critical evaluation of the safety of Cimicifuga racemosa in menopause symptom relief. Menopause. 2003, 10, 299-313.
64. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause. 2003, 10, 58-64.
65. Minciullo P, Saija A, Patafi M, [et al.]. Muscle damage induced by black cohosh (Cimicifuga racemosa). Phytomedicine. 2006, 13, 115-118.
66. Meyer S, Vogt T, Obermann E, [et al.]. Cutaneous pseudolymphoma induced by Cimicifuga racemosa. Dermatology. 2007, 214, 94-96.
67. Ingraffea A, Donohue K, Wilkel C, [et al.]. Cutaneous vasculitis in two patients taking an herbal supplement containing black cohosh. J Am Acad Dermatol. 2007, 56 suppl. 5, S124-S126.
68. Whiting P, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. 2002, 177, 440-443.
69. Lontos S, Jones R, Angus P, [et al.]. Acute liver failure associated with the use of herbal preparations cntaining black cohosh. Med J Aust. 2003, 179, 390-391.
70. Cohen S, O'Connor A, Hart J, [et al.]. Autoimmune hepatitis associated with the use of black cohosh: a case study. Menopause. 2004, 11, 575-577.
71. Levitsky J, Alli T, Wisecarver J, [et al.]. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci. 2005, 50, 538-539.
72. Lynch C, Folkers M, Hutson W. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl. 2006, 12, 989-992.
73. Thomsen M, Schmidt M. Hepatotoxicity from Cimicifuga racemosa? Recent Australian case report not sufficiently substantiated. J Altern Complement Med. 2003, 9, 337-340.
74. Workshop on the Safety of Black Cohosh in Clinical Studies. National Center of Complementary and Alternative Medicine and Office of Dietary Supplements, National Institutes of Health. November 22, 2004. Dostepne w Internecie: http://nccam.nih.gov/news/partmeeting/ blackcohosh_mtngsumm.pdf.
75. Therapeutic Goods Administration. Black cohosh (Cimicifuga racemosa). New labeling and consumer information for medicines containing black (Cimicifuga racemosa). February 9, 2006. Dostepne w Internecie: http://www.tga.gov.au/cm/blkcohosh.htm.
76. MHRA action on safety concerns over Black Cohosh and liver injury. 18th July 2006. Dostepne w Internecie: http://www.ahpa.org/portals/0/ pdfs/06_0718_PR_MHRA.pdf.
77. EMEA Public Statement on herbal medicinal products containing Cimicifuga racemosae rhizoma (black cohosh. Root) - serious hepatic reactions -. Dostepne w Internecie: http://www.emea.eu.int/pdfs/ human/hmpc/26925906en.pdf.
78. Informagia Prezesa Urzedu Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych dotyczaca mozliwego Zwiazku meidy stosowaniem preparatów zawierajacych wyciag z korzenia pluskwicy groniastej (Cimicifuga racemosa rhizoma) i wystepowaniem ciezkich uszkodzeń watroby. Dostepne w Internecie: http://www.urpl.gov.pl/komunikaty/pluskwica.pdf.
79. Gori L, Firenzuoli F. Is black cohosh a hepatotoxic medicinal herb? Forsch Komplement Med. 2007, 14, 109-110.
80. Walji R, Boon H, Guns E, [et al.]. Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Support Care Cancer. 2007, 15, 913-921.